Table 4.

Distribution of drug treatment among persistent PAH.

	Persistent PAH n = 695 (%)
PAH treatment before 2010	40 (5.8)
PAH treatment in 2010 or after	655 (94.2)
Monotherapy among children with PAH treatment in 2010 or after
One drug category during follow-up
Total	528 (80.6)
PDE-5 inhibitors	449 (68.5)
Endothelin receptor antagonists	9 (1.4)
CCBs	59 (9.0)
Prostanoids	11 (1.7)
Two drug categories during follow-up (one mono switched to another mono therapy)
Total	18 (2.7)
PDE-5 inhibitors to CCBs	8 (1.2)
PDE-5 inhibitors to endothelin  receptor antagonists	3 (0.5)
PDE-5 inhibitors to prostanoids	2 (0.3)
CCBs to PDE-5 inhibitors	3 (0.5)
CCBs to endothelin receptor  antagonists	1 (0.2)
Endothelin receptor antagonists to  PDE-5 inhibitors	1 (0.2)
Concomitant dual therapy among children with PAH treatment in 2010 or after
Total	86 (13.1)
PDE-5 inhibitors + endothelin  receptor antagonists	49 (7.5)
PDE-5 inhibitors + CCBs	14 (2.1)
PDE-5 inhibitors + prostanoids	18 (2.7)
Endothelin receptor  antagonists + prostanoids	2 (0.3)
Others*	3 (0.5)
Concomitant triple therapy among children with PAH treatment in 2010 or after
Total	21 (3.2)
PDE-5 inhibitors + endothelin  receptor antagonists + CCBs	2 (0.3)
PDE-5 inhibitors + endothelin  receptor antagonists +   prostanoids	18 (2.7)
Endothelin receptor antagonists +    CCBs + prostanoids	1 (0.2)
Concomitant quad therapy among children with PAH treatment in 2010 or after
PDE-5 inhibitors + endothelin  receptor antagonists + CCBs +   prostanoids	2 (0.3)

^*Switched from one dual therapy to another.